logo
‘Dragon Man' DNA revelation puts a face to a mysterious group of ancient humans

‘Dragon Man' DNA revelation puts a face to a mysterious group of ancient humans

CNN19-06-2025
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
CNN —
An enigmatic skull recovered from the bottom of a well in northeastern China in 2018 sparked intrigue when it didn't match any previously known species of prehistoric human. Now, scientists say they have found evidence of where the fossil fits, and it could be a key piece in another cryptic evolutionary puzzle.
After several failed attempts, the researchers managed to extract genetic material from the fossilized cranium — nicknamed Dragon Man — linking it to an enigmatic group of early humans known as Denisovans. A dozen or so Denisovan fossilized bone fragments had previously been found and identified using ancient DNA. But the specimens' small size offered little idea of what this shadowy population of ancient hominins looked like, and the group has never been assigned an official scientific name.
Scientists typically consider skulls, with telltale bumps and ridges, the best type of fossilized remains to understand the form or appearance of an extinct hominin species. The new findings, if confirmed, could effectively put a face to the Denisovan name.
'I really feel that we have cleared up some of the mystery surrounding this population,' said Qiaomei Fu, a professor at the Institute of Paleontology and Paleoanthropology, part of the Chinese Academy of Sciences in Beijing, and lead author of the new research. 'After 15 years, we know the first Denisovan skull.'
Denisovans were first discovered in 2010 by a team that included Fu — who was then a young researcher at the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany — from ancient DNA contained in a pinkie fossil found in Denisova Cave in the Altai Mountains of Russia. Additional remains unearthed in the cave, from which the group gets its name, and elsewhere in Asia continue to add to the still-incomplete picture.
The new research, described in two scientific papers published Wednesday, is 'definitely going to be among, if not the, biggest paleoanthropology papers of the year,' and will spur debate in the field 'for quite some time,' said Ryan McRae, a paleoanthropologist at the Smithsonian National Museum of Natural History in Washington, DC, who was not involved in the studies.
The findings could help fill in gaps about a time when Homo sapiens weren't the only humans roaming the planet — and teach scientists more about modern humans. Our species once coexisted for tens of thousands of years and interbred with both Denisovans and Neanderthals before the two went extinct. Most humans today carry a genetic legacy of those ancient encounters. Neanderthal fossils have been the subject of study for than a century, but scant details are known about our mysterious Denisovan cousins, and a skull fossil can reveal a great deal.
Long in the tooth
A laborer in the city of Harbin in northeastern China discovered the Dragon Man skull in 1933. The man, who was constructing a bridge over the Songhua River when that part of the country was under Japanese occupation, took home the specimen and stored it at the bottom of a well for safekeeping.
The man never retrieved his treasure, and the cranium, with one tooth still attached in the upper jaw, remained unknown to science for decades until his relatives learned about it before his death. His family donated the fossil to Hebei GEO University, and researchers first described it in a set of studies published in 2021 that found the skull to be at least 146,000 years old.
The researchers argued that the fossil merited a new species name given the unique nature of the skull, naming it Homo longi — which is derived from Heilongjiang, or Black Dragon River, the province where the cranium was found. Some experts at the time hypothesized that the skull might be Denisovan, while others have lumped the cranium in with a cache of difficult-to-classify fossils found in China, resulting in intense debate and making molecular data from the fossil particularly valuable.
Given the skull's age and backstory, Fu said she knew it would be challenging to extract ancient DNA from the fossil to better understand where it fit in the human family tree. 'There are only bones from 4 sites over 100,000 (years old) in the world that have ancient DNA,' she noted via email.
Fu and her colleagues attempted to retrieve ancient DNA from six samples taken from Dragon Man's surviving tooth and the cranium's petrous bone, a dense piece at the base of the skull that's often a rich source of DNA in fossils, without success.
The team also tried to retrieve genetic material from the skull's dental calculus — the gunk left on teeth that can over time form a hard layer and preserve DNA from the mouth. From this process, the researchers managed to recover mitochondrial DNA, which is less detailed than nuclear DNA but revealed a link between the sample and the known Denisovan genome, according to one new paper published in the journal Cell.
'Mitochondrial DNA is only a small portion of the total genome but can tell us a lot. The limitations lie in its relatively small size compared to nuclear DNA and in the fact that it is only inherited from the matrilineal side, not both biological parents,' McRae said.
'Therefore, without nuclear DNA a case could be made that this individual is a hybrid with a Denisovan mother, but I think that scenario is rather less likely than this fossil belonging to a full Denisovan,' he added.
Mounting evidence
The team additionally recovered protein fragments from the petrous bone samples, the analysis of which also suggested the Dragon Man skull belonged to a Denisovan population, according to a separate paper published Wednesday in the journal Science.
Together, 'these papers increase the impact of establishing the Harbin cranium as a Denisovan,' Fu said.
The molecular data provided by the two papers is potentially very important, said anthropologist Chris Stringer, research leader in human origins at London's Natural History Museum.
'I have been collaborating with Chinese scientists on new morphological analyses of human fossils, including Harbin,' he said. 'Combined with our studies, this work makes it increasingly likely that Harbin is the most complete fossil of a Denisovan found so far.'
However, Xijun Ni, a professor at the Institute of Vertebrate Paleontology and Paleoanthropology in Beijing who, along with Stringer, worked on the initial Dragon Man research but not the latest studies, said that he is cautious about the outcome of the two papers because some of the DNA extraction methods used were 'experimental.' Ni also said he finds it strange that DNA was obtained from surface dental calculus but not inside the tooth and petrous bone, given that the calculus appeared to be more exposed to potential contamination.
Nonetheless, he added that he thinks it is likely the skull and other fossils identified as Denisovan are from the same human species.
The goal in using a new extraction approach was to recover as much genetic material as possible, Fu explained, adding that the dense crystalline structure of dental calculus may help prevent the host DNA from being lost.
The protein signatures Fu and her team recovered indicated 'a Denisovan attribution, with other attributions very unlikely,' said Frido Welker, an associate professor of biomolecular paleoanthropology at the University of Copenhagen's Globe Institute in Denmark. Welker has recovered Denisovan proteins from other candidate fossils but was not involved in this research.
'With the Harbin cranium now linked to Denisovans based on molecular evidence, a larger portion of the hominin fossil record can be compared reliably to a known Denisovan specimen based on morphology,' he said.
A name and a face for Denisovans
With the Dragon Man skull now linked to Denisovans based on molecular evidence, it will be easier for paleoanthropologists to classify other potential Denisovan remains from China and elsewhere. McRae, Ni and Stringer all said they thought it was likely that Homo longi would become the official species name for Denisovans, although other names have been proposed.
'Renaming the entire suite of Denisovan evidence as Homo longi is a bit of a step, but one that has good standing since the scientific name Homo longi was technically the first to be, now, tied to Denisovan fossils,' McRae said. However, he added that he doubts the informal name of Denisovan is going anywhere anytime soon, suggesting it might become shorthand for the species, as Neanderthal is to Homo neanderthalensis.
The findings also make it possible to say a little more about what Denisovans might have looked like, assuming the Dragon Man skull belonged to a typical individual. According to McRae, the ancient human would have had very strong brow ridges, brains 'on par in size to Neanderthals and modern humans' but larger teeth than both cousins. Overall, Denisovans would have had a blocky and robust-looking appearance.
'As with the famous image of a Neanderthal dressed in modern attire, they would most likely still be recognizable as 'human,'' McRae said.
'They are still our more mysterious cousin, just slightly less so than before,' he added. 'There is still a lot of work to be done to figure out exactly who the Denisovans were and how they are related to us and other hominins.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NASA is putting a nuclear reactor on the moon. It could reshape space governance
NASA is putting a nuclear reactor on the moon. It could reshape space governance

Fast Company

time11 hours ago

  • Fast Company

NASA is putting a nuclear reactor on the moon. It could reshape space governance

The first space race was about flags and footprints. Now, decades later, landing on the moon is old news. The new race is to build there, and doing so hinges on power. In April 2025, China reportedly unveiled plans to build a nuclear power plant on the moon by 2035. This plant would support its planned international lunar research station. The United States countered in August, when acting NASA Administrator Sean Duffy reportedly suggested a U.S. reactor would be operational on the moon by 2030. While it might feel like a sudden sprint, this isn't exactly breaking news. NASA and the Department of Energy have spent years quietly developing small nuclear power systems to power lunar bases, mining operations, and long-term habitats. As a space lawyer focused on long-term human advancement into space, I see this not as an arms race but as a strategic infrastructure race. And in this case, infrastructure is influence. A lunar nuclear reactor may sound dramatic, but it's neither illegal nor unprecedented. If deployed responsibly, it could allow countries to peacefully explore the moon, fuel their economic growth, and test out technologies for deeper space missions. But building a reactor also raises critical questions about access and power. The legal framework already exists Nuclear power in space radioisotope generators that use small amounts of radioactive elements—a type of nuclear fuel— to power satellites, Mars rovers, and the Voyager probes. The United Nations' 1992 Principles Relevant to the Use of Nuclear Power Sources in Outer Space, a nonbinding resolution, recognizes that nuclear energy may be essential for missions where solar power is insufficient. This resolution sets guidelines for safety, transparency, and international consultation. Nothing in international law prohibits the peaceful use of nuclear power on the moon. But what matters is how countries deploy it. And the first country to succeed could shape the norms for expectations, behaviors, and legal interpretations related to lunar presence and influence. Why being first matters The 1967 Outer Space Treaty, ratified by all major spacefaring nations including the U.S., China, and Russia, governs space activity. Its Article IX requires that states act with 'due regard to the corresponding interests of all other States Parties.' That statement means if one country places a nuclear reactor on the moon, others must navigate around it, legally and physically. In effect, it draws a line on the lunar map. If the reactor anchors a larger, long-term facility, it could quietly shape what countries do and how their moves are interpreted legally, on the moon and beyond. Other articles in the Outer Space Treaty set similar boundaries on behavior, even as they encourage cooperation. They affirm that all countries have the right to freely explore and access the moon and other celestial bodies, but they explicitly prohibit territorial claims or assertions of sovereignty. At the same time, the treaty acknowledges that countries may establish installations such as bases—and with that, gain the power to limit access. While visits by other countries are encouraged as a transparency measure, they must be preceded by prior consultations. Effectively, this grants operators a degree of control over who can enter and when. Building infrastructure is not staking a territorial claim. No one can own the moon, but one country setting up a reactor could shape where and how others operate—functionally, if not legally. Infrastructure is influence where ice found in perpetually shadowed craters could fuel rockets and sustain lunar bases. These sought-after regions are scientifically vital and geopolitically sensitive, as multiple countries want to build bases or conduct research there. Building infrastructure in these areas would cement a country's ability to access the resources there and potentially exclude others from doing the same. Critics may worry about radiation risks. Even if designed for peaceful use and contained properly, reactors introduce new environmental and operational hazards, particularly in a dangerous setting such as space. But the U.N. guidelines do outline rigorous safety protocols, and following them could potentially mitigate these concerns. Why nuclear? Because solar has limits The moon has little atmosphere and experiences 14-day stretches of darkness. In some shadowed craters, where ice is likely to be found, sunlight never reaches the surface at all. These issues make solar energy unreliable, if not impossible, in some of the most critical regions. A small lunar reactor could operate continuously for a decade or more, powering habitats, rovers, 3D printers, and life-support systems. Nuclear power could be the linchpin for long-term human activity. And it's not just about the Moon—developing this capability is essential for missions to Mars, where solar power is even more constrained. A call for governance, not alarm The United States has an opportunity to lead not just in technology but in governance. If it commits to sharing its plans publicly, following Article IX of the Outer Space Treaty and reaffirming a commitment to peaceful use and international participation, it will encourage other countries to do the same. The future of the moon won't be determined by who plants the most flags. It will be determined by who builds what, and how. Nuclear power may be essential for that future. Building transparently and in line with international guidelines would allow countries to more safely realize that future. A reactor on the moon isn't a territorial claim or a declaration of war. But it is infrastructure. And infrastructure will be how countries display power—of all kinds—in the next era of space exploration. Michelle L.D. Hanlon is a professor of air and space law at the University of Mississippi. The early-rate deadline for Fast Company's Most Innovative Companies Awards is Friday, September 5, at 11:59 p.m. PT. Apply today.

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes
Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

Medscape

timea day ago

  • Medscape

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

TOPLINE: In euthyroid patients with type 2 diabetes (T2D), relatively higher free triiodothyronine (FT3) levels within the normal range were linked to a lower risk for diabetic peripheral neuropathy and better nerve function. METHODOLOGY: In euthyroid patients with T2D, lower FT3 levels within the normal range can worsen glucose and lipid metabolism and increase the risk for nephropathy and retinopathy, but the association of FT3 levels with peripheral neuropathy remains unclear. Researchers in China examined the relationship between FT3 levels and diabetic peripheral neuropathy in 1422 euthyroid patients with T2D (mean age, 58.04 years; 33.97% women) who underwent electromyography during hospitalization. Participants were considered euthyroid if their thyroid-stimulating hormone level was 0.25-5.5 IU/mL, free thyroxine level was 9.0-25.5 pmol/L, and FT3 level was 2.5-7.0 pmol/L. A diagnosis of diabetic peripheral neuropathy was made in those who showed neuropathic symptoms (neuropathic pain, paresthesias, numbness, sensory distortion, unsteadiness, or falls) and signs (pain sensation abnormalities, vibration sensation abnormalities, loss of the ankle reflex, touch/pressure sensation abnormalities, or temperature sensation abnormalities) during or after confirmed diabetes diagnosis. Nerve conduction studies of the distal limbs (median, ulnar, common peroneal, sural, and superficial peroneal nerves) were conducted in all participants, and distal motor and sensory nerve latencies, action potential amplitudes, and conduction velocities of motor and sensory nerves were recorded. TAKEAWAY: Among all participants with T2D, the 519 who were diagnosed with diabetic peripheral neuropathy showed significantly lower serum FT3 levels than those without the condition (P < .001). The risk for diabetic peripheral neuropathy was reduced in participants with FT3 levels between 4.3 and 4.7 pmol/L (odds ratio [OR], 0.57; 95% CI, 0.39-0.81) and 4.7 and 7.0 pmol/L (OR, 0.33; 95% CI, 0.21-0.52) compared with those with FT3 levels between 2.5 and 3.8 pmol/L. Participants with neuropathy had slower, weaker nerve responses and longer latencies than those without, with higher FT3 levels in patients with diabetic peripheral neuropathy being linked to faster nerve conduction and shorter latencies. A Mendelian randomization analysis using the ThyroidOmics Consortium and the UK Biobank genome-wide association study data also indicated a causal relationship between low FT3 levels and the risk for diabetic peripheral neuropathy (inverse variance weighted β = -0.655; P = .035). IN PRACTICE: 'Within the normal range, a relatively high level of FT3 (> 4.3 pmol/L) was associated with a reduced risk of DPN [diabetic peripheral neuropathy]. Thyroid hormones may be beneficial for patients with DPN if their FT3 levels are near the low end of the normal range,' the authors of the study wrote. SOURCE: This study was led by Bing'er Xu, Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China. It was published online in the Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: This study was limited by its single-center design and focused on hospitalized patients with T2D in Shanghai. It measured only specific peripheral nerves' conduction parameters. The Mendelian randomization analysis was conducted only in Europeans, requiring validation in other ethnic populations. DISCLOSURES: This study received support from the National Science and Technology Major Project, the National Natural Science Foundation of China, the Science and Technology Commission of Shanghai Municipality, and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033

Yahoo

timea day ago

  • Yahoo

Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033

The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store